Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP805563.RA-0Zi5DWE0TOhpKj9Dwq7-QGnJ86YSCT-rUuJ0nmFXco130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP805563.RA-0Zi5DWE0TOhpKj9Dwq7-QGnJ86YSCT-rUuJ0nmFXco130_assertion type Assertion NP805563.RA-0Zi5DWE0TOhpKj9Dwq7-QGnJ86YSCT-rUuJ0nmFXco130_head.
- NP805563.RA-0Zi5DWE0TOhpKj9Dwq7-QGnJ86YSCT-rUuJ0nmFXco130_assertion description "[Furthermore, the greater risk for the double variant of p53 and XRCC1 in the SOD2 Val/Val genotype group was specific only for patients with adenocarcinoma and not for patients with squamous cell carcinoma, with adjusted ORs of 3.31 (95% CI, 1.68-6.51) and 0.69 (95% CI, 0.24-2.02), respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP805563.RA-0Zi5DWE0TOhpKj9Dwq7-QGnJ86YSCT-rUuJ0nmFXco130_provenance.
- NP805563.RA-0Zi5DWE0TOhpKj9Dwq7-QGnJ86YSCT-rUuJ0nmFXco130_assertion evidence source_evidence_literature NP805563.RA-0Zi5DWE0TOhpKj9Dwq7-QGnJ86YSCT-rUuJ0nmFXco130_provenance.
- NP805563.RA-0Zi5DWE0TOhpKj9Dwq7-QGnJ86YSCT-rUuJ0nmFXco130_assertion SIO_000772 15534883 NP805563.RA-0Zi5DWE0TOhpKj9Dwq7-QGnJ86YSCT-rUuJ0nmFXco130_provenance.
- NP805563.RA-0Zi5DWE0TOhpKj9Dwq7-QGnJ86YSCT-rUuJ0nmFXco130_assertion wasDerivedFrom befree-20140225 NP805563.RA-0Zi5DWE0TOhpKj9Dwq7-QGnJ86YSCT-rUuJ0nmFXco130_provenance.
- NP805563.RA-0Zi5DWE0TOhpKj9Dwq7-QGnJ86YSCT-rUuJ0nmFXco130_assertion wasGeneratedBy ECO_0000203 NP805563.RA-0Zi5DWE0TOhpKj9Dwq7-QGnJ86YSCT-rUuJ0nmFXco130_provenance.